APO Research
Talk to an analyst

APO RESEARCH · REPORT

KI-67 Antibody

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global KI-67 Antibody Market Analysis and Forecast 2026-2032

19 December 2025192 pages

Choose your research edition.

Industry ResearchKI-67 Antibody Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal KI-67 Antibody Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal KI-67 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal KI-67 Antibody Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal KI-67 Antibody Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global KI-67 Antibody market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for KI-67 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for KI-67 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for KI-67 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for KI-67 Antibody is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of KI-67 Antibody include Atlas Antibodies, BD Biosciences, Beckman Coulter, Bio-Rad, FineTest, Leica Biosystems, Miltenyi Biotec, Miltenyi Biotec and NSJ Bioreagents, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for KI-67 Antibody, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of KI-67 Antibody, also provides the revenue of main regions and countries. Of the upcoming market potential for KI-67 Antibody, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the KI-67 Antibody revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global KI-67 Antibody market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for KI-67 Antibody revenue, projected growth trends, production technology, application and end-user industry.

KI-67 Antibody Segment by Company

Atlas Antibodies

BD Biosciences

Beckman Coulter

Bio-Rad

FineTest

Leica Biosystems

Miltenyi Biotec

Miltenyi Biotec

NSJ Bioreagents

Proteintech

Synaptic

United States Biological

Merck

Thermo Fisher Scientific

KI-67 Antibody Segment by Type

Polyclonal

Monoclonal

KI-67 Antibody Segment by Application

Immunohistochemistry Paraffin

Immunohistochemistry Frozen

Immunofluorescence

Western Blot

Others

KI-67 Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global KI-67 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of KI-67 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of KI-67 Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of KI-67 Antibody in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of KI-67 Antibody company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, KI-67 Antibody revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global KI-67 Antibody Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Polyclonal Major Player Table 3. Monoclonal Major Player Table 4. Global KI-67 Antibody Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Immunohistochemistry Paraffin Major Player Table 6. Immunohistochemistry Frozen Major Player Table 7. Immunofluorescence Major Player Table 8. Western Blot Major Player Table 9. Others Major Player Table 10. KI-67 Antibody Industry Trends Table 11. KI-67 Antibody Industry Drivers Table 12. KI-67 Antibody Industry Opportunities and Challenges Table 13. KI-67 Antibody Industry Restraints Table 14. Global KI-67 Antibody Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global KI-67 Antibody Market Size by Region (2021-2026) & (US$ Million) Table 16. Global KI-67 Antibody Market Share by Region (2021-2026) Table 17. Global KI-67 Antibody Market Size by Region (2027-2032) & (US$ Million) Table 18. Global KI-67 Antibody Market Share by Region (2027-2032) Table 19. Global KI-67 Antibody Revenue by Players (US$ Million) & (2021-2026) Table 20. Global KI-67 Antibody Revenue Market Share by Players (2021-2026) Table 21. Global KI-67 Antibody Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global KI-67 Antibody Key Players Headquarters & Area Served Table 23. Global KI-67 Antibody Players, Product Type & Application Table 24. Global KI-67 Antibody Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global KI-67 Antibody by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global KI-67 Antibody Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global KI-67 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 29. Global KI-67 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 30. Global KI-67 Antibody Revenue Market Share by Type (2021-2026) Table 31. Global KI-67 Antibody Revenue Market Share by Type (2027-2032) Table 32. Global KI-67 Antibody Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global KI-67 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 34. Global KI-67 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 35. Global KI-67 Antibody Revenue Market Share by Application (2021-2026) Table 36. Global KI-67 Antibody Revenue Market Share by Application (2027-2032) Table 37. Atlas Antibodies Company Information Table 38. Atlas Antibodies Business Overview Table 39. Atlas Antibodies KI-67 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Atlas Antibodies KI-67 Antibody Product Portfolio Table 41. Atlas Antibodies Recent Development Table 42. BD Biosciences Company Information Table 43. BD Biosciences Business Overview Table 44. BD Biosciences KI-67 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. BD Biosciences KI-67 Antibody Product Portfolio Table 46. BD Biosciences Recent Development Table 47. Beckman Coulter Company Information Table 48. Beckman Coulter Business Overview Table 49. Beckman Coulter KI-67 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Beckman Coulter KI-67 Antibody Product Portfolio Table 51. Beckman Coulter Recent Development Table 52. Bio-Rad Company Information Table 53. Bio-Rad Business Overview Table 54. Bio-Rad KI-67 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Bio-Rad KI-67 Antibody Product Portfolio Table 56. Bio-Rad Recent Development Table 57. FineTest Company Information Table 58. FineTest Business Overview Table 59. FineTest KI-67 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. FineTest KI-67 Antibody Product Portfolio Table 61. FineTest Recent Development Table 62. Leica Biosystems Company Information Table 63. Leica Biosystems Business Overview Table 64. Leica Biosystems KI-67 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Leica Biosystems KI-67 Antibody Product Portfolio Table 66. Leica Biosystems Recent Development Table 67. Miltenyi Biotec Company Information Table 68. Miltenyi Biotec Business Overview Table 69. Miltenyi Biotec KI-67 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Miltenyi Biotec KI-67 Antibody Product Portfolio Table 71. Miltenyi Biotec Recent Development Table 72. Miltenyi Biotec Company Information Table 73. Miltenyi Biotec Business Overview Table 74. Miltenyi Biotec KI-67 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Miltenyi Biotec KI-67 Antibody Product Portfolio Table 76. Miltenyi Biotec Recent Development Table 77. NSJ Bioreagents Company Information Table 78. NSJ Bioreagents Business Overview Table 79. NSJ Bioreagents KI-67 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. NSJ Bioreagents KI-67 Antibody Product Portfolio Table 81. NSJ Bioreagents Recent Development Table 82. Proteintech Company Information Table 83. Proteintech Business Overview Table 84. Proteintech KI-67 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Proteintech KI-67 Antibody Product Portfolio Table 86. Proteintech Recent Development Table 87. Synaptic Company Information Table 88. Synaptic Business Overview Table 89. Synaptic KI-67 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. Synaptic KI-67 Antibody Product Portfolio Table 91. Synaptic Recent Development Table 92. United States Biological Company Information Table 93. United States Biological Business Overview Table 94. United States Biological KI-67 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. United States Biological KI-67 Antibody Product Portfolio Table 96. United States Biological Recent Development Table 97. Merck Company Information Table 98. Merck Business Overview Table 99. Merck KI-67 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Merck KI-67 Antibody Product Portfolio Table 101. Merck Recent Development Table 102. Thermo Fisher Scientific Company Information Table 103. Thermo Fisher Scientific Business Overview Table 104. Thermo Fisher Scientific KI-67 Antibody Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Thermo Fisher Scientific KI-67 Antibody Product Portfolio Table 106. Thermo Fisher Scientific Recent Development Table 107. North America KI-67 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 108. North America KI-67 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 109. North America KI-67 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 110. North America KI-67 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 111. North America KI-67 Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. North America KI-67 Antibody Revenue by Country (2021-2026) & (US$ Million) Table 113. North America KI-67 Antibody Revenue by Country (US$ Million) & (2027-2032) Table 114. Europe KI-67 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 115. Europe KI-67 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 116. Europe KI-67 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 117. Europe KI-67 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 118. Europe KI-67 Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 119. Europe KI-67 Antibody Revenue by Country (2021-2026) & (US$ Million) Table 120. Europe KI-67 Antibody Revenue by Country (US$ Million) & (2027-2032) Table 121. China KI-67 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 122. China KI-67 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 123. China KI-67 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 124. China KI-67 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 125. Asia KI-67 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 126. Asia KI-67 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 127. Asia KI-67 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 128. Asia KI-67 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 129. Asia KI-67 Antibody Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 130. Asia KI-67 Antibody Revenue by Region (US$ Million) & (2021-2026) Table 131. Asia KI-67 Antibody Revenue by Region (US$ Million) & (2027-2032) Table 132. SAMEA KI-67 Antibody Revenue by Type (2021-2026) & (US$ Million) Table 133. SAMEA KI-67 Antibody Revenue by Type (2027-2032) & (US$ Million) Table 134. SAMEA KI-67 Antibody Revenue by Application (2021-2026) & (US$ Million) Table 135. SAMEA KI-67 Antibody Revenue by Application (2027-2032) & (US$ Million) Table 136. SAMEA KI-67 Antibody Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 137. SAMEA KI-67 Antibody Revenue by Country (2021-2026) & (US$ Million) Table 138. SAMEA KI-67 Antibody Revenue by Country (US$ Million) & (2027-2032) Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. KI-67 Antibody Image Figure 2. Global KI-67 Antibody Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global KI-67 Antibody Market Size Share 2021 VS 2025 VS 2032 Figure 4. Polyclonal Image Figure 5. Monoclonal Image Figure 6. Global KI-67 Antibody Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global KI-67 Antibody Market Size Share 2021 VS 2025 VS 2032 Figure 8. Immunohistochemistry Paraffin Image Figure 9. Immunohistochemistry Frozen Image Figure 10. Immunofluorescence Image Figure 11. Western Blot Image Figure 12. Others Image Figure 13. Global KI-67 Antibody Market Size (US$ Million) & (2021-2032) Figure 14. Global KI-67 Antibody Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global KI-67 Antibody Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global KI-67 Antibody Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global KI-67 Antibody Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global KI-67 Antibody Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global KI-67 Antibody Revenue Market Share by Type (2021-2032) Figure 21. Global KI-67 Antibody Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global KI-67 Antibody Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global KI-67 Antibody Revenue Market Share by Application (2021-2032) Figure 24. North America KI-67 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America KI-67 Antibody Revenue Share by Type (2021-2032) Figure 26. North America KI-67 Antibody Revenue Share by Application (2021-2032) Figure 27. North America KI-67 Antibody Revenue Share by Country (2021-2032) Figure 28. United States KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe KI-67 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe KI-67 Antibody Revenue Share by Type (2021-2032) Figure 33. Europe KI-67 Antibody Revenue Share by Application (2021-2032) Figure 34. Europe KI-67 Antibody Revenue Share by Country (2021-2032) Figure 35. Germany KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China KI-67 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China KI-67 Antibody Revenue Share by Type (2021-2032) Figure 45. China KI-67 Antibody Revenue Share by Application (2021-2032) Figure 46. Asia KI-67 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia KI-67 Antibody Revenue Share by Type (2021-2032) Figure 48. Asia KI-67 Antibody Revenue Share by Application (2021-2032) Figure 49. Asia KI-67 Antibody Revenue Share by Region (2021-2032) Figure 50. Japan KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA KI-67 Antibody Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA KI-67 Antibody Revenue Share by Type (2021-2032) Figure 58. SAMEA KI-67 Antibody Revenue Share by Application (2021-2032) Figure 59. SAMEA KI-67 Antibody Revenue Share by Country (2021-2032) Figure 60. Brazil KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt KI-67 Antibody Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Immunohistochemistry Paraffin
  • Immunohistochemistry Frozen
  • Immunofluorescence
  • Western Blot
  • Others
Companies covered
  • Atlas Antibodies
  • BD Biosciences
  • Beckman Coulter
  • Bio-Rad
  • FineTest
  • Leica Biosystems
  • Miltenyi Biotec
  • Miltenyi Biotec
  • NSJ Bioreagents
  • Proteintech
  • Synaptic
  • United States Biological
  • Merck
  • Thermo Fisher Scientific

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 KI-67 Antibody Market by Type
  3. 1.2.1 Global KI-67 Antibody Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Polyclonal
  5. 1.2.3 Monoclonal
  6. 1.3 KI-67 Antibody Market by Application
  7. 1.3.1 Global KI-67 Antibody Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Immunohistochemistry Paraffin
  9. 1.3.3 Immunohistochemistry Frozen
  10. 1.3.4 Immunofluorescence
  11. 1.3.5 Western Blot
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 KI-67 Antibody Market Dynamics
  1. 2.1 KI-67 Antibody Industry Trends
  2. 2.2 KI-67 Antibody Industry Drivers
  3. 2.3 KI-67 Antibody Industry Opportunities and Challenges
  4. 2.4 KI-67 Antibody Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global KI-67 Antibody Market Perspective (2021-2032)
  2. 3.2 Global KI-67 Antibody Growth Trends by Region
  3. 3.2.1 Global KI-67 Antibody Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global KI-67 Antibody Market Size by Region (2021-2026)
  5. 3.2.3 Global KI-67 Antibody Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global KI-67 Antibody Revenue by Players
  2. 4.1.1 Global KI-67 Antibody Revenue by Players (2021-2026)
  3. 4.1.2 Global KI-67 Antibody Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global KI-67 Antibody Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global KI-67 Antibody Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global KI-67 Antibody Key Players Headquarters & Area Served
  7. 4.4 Global KI-67 Antibody Players, Product Type & Application
  8. 4.5 Global KI-67 Antibody Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global KI-67 Antibody Market CR5 and HHI
  11. 4.6.3 2025 KI-67 Antibody Tier 1, Tier 2, and Tier 3
5 KI-67 Antibody Market Size by Type
  1. 5.1 Global KI-67 Antibody Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global KI-67 Antibody Revenue by Type (2021-2032)
  3. 5.3 Global KI-67 Antibody Revenue Market Share by Type (2021-2032)
6 KI-67 Antibody Market Size by Application
  1. 6.1 Global KI-67 Antibody Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global KI-67 Antibody Revenue by Application (2021-2032)
  3. 6.3 Global KI-67 Antibody Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Atlas Antibodies
  2. 7.1.1 Atlas Antibodies Company Information
  3. 7.1.2 Atlas Antibodies Business Overview
  4. 7.1.3 Atlas Antibodies KI-67 Antibody Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Atlas Antibodies KI-67 Antibody Product Portfolio
  6. 7.1.5 Atlas Antibodies Recent Developments
  7. 7.2 BD Biosciences
  8. 7.2.1 BD Biosciences Company Information
  9. 7.2.2 BD Biosciences Business Overview
  10. 7.2.3 BD Biosciences KI-67 Antibody Revenue and Gross Margin (2021-2026)
  11. 7.2.4 BD Biosciences KI-67 Antibody Product Portfolio
  12. 7.2.5 BD Biosciences Recent Developments
  13. 7.3 Beckman Coulter
  14. 7.3.1 Beckman Coulter Company Information
  15. 7.3.2 Beckman Coulter Business Overview
  16. 7.3.3 Beckman Coulter KI-67 Antibody Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Beckman Coulter KI-67 Antibody Product Portfolio
  18. 7.3.5 Beckman Coulter Recent Developments
  19. 7.4 Bio-Rad
  20. 7.4.1 Bio-Rad Company Information
  21. 7.4.2 Bio-Rad Business Overview
  22. 7.4.3 Bio-Rad KI-67 Antibody Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bio-Rad KI-67 Antibody Product Portfolio
  24. 7.4.5 Bio-Rad Recent Developments
  25. 7.5 FineTest
  26. 7.5.1 FineTest Company Information
  27. 7.5.2 FineTest Business Overview
  28. 7.5.3 FineTest KI-67 Antibody Revenue and Gross Margin (2021-2026)
  29. 7.5.4 FineTest KI-67 Antibody Product Portfolio
  30. 7.5.5 FineTest Recent Developments
  31. 7.6 Leica Biosystems
  32. 7.6.1 Leica Biosystems Company Information
  33. 7.6.2 Leica Biosystems Business Overview
  34. 7.6.3 Leica Biosystems KI-67 Antibody Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Leica Biosystems KI-67 Antibody Product Portfolio
  36. 7.6.5 Leica Biosystems Recent Developments
  37. 7.7 Miltenyi Biotec
  38. 7.7.1 Miltenyi Biotec Company Information
  39. 7.7.2 Miltenyi Biotec Business Overview
  40. 7.7.3 Miltenyi Biotec KI-67 Antibody Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Miltenyi Biotec KI-67 Antibody Product Portfolio
  42. 7.7.5 Miltenyi Biotec Recent Developments
  43. 7.8 Miltenyi Biotec
  44. 7.8.1 Miltenyi Biotec Company Information
  45. 7.8.2 Miltenyi Biotec Business Overview
  46. 7.8.3 Miltenyi Biotec KI-67 Antibody Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Miltenyi Biotec KI-67 Antibody Product Portfolio
  48. 7.8.5 Miltenyi Biotec Recent Developments
  49. 7.9 NSJ Bioreagents
  50. 7.9.1 NSJ Bioreagents Company Information
  51. 7.9.2 NSJ Bioreagents Business Overview
  52. 7.9.3 NSJ Bioreagents KI-67 Antibody Revenue and Gross Margin (2021-2026)
  53. 7.9.4 NSJ Bioreagents KI-67 Antibody Product Portfolio
  54. 7.9.5 NSJ Bioreagents Recent Developments
  55. 7.10 Proteintech
  56. 7.10.1 Proteintech Company Information
  57. 7.10.2 Proteintech Business Overview
  58. 7.10.3 Proteintech KI-67 Antibody Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Proteintech KI-67 Antibody Product Portfolio
  60. 7.10.5 Proteintech Recent Developments
  61. 7.11 Synaptic
  62. 7.11.1 Synaptic Company Information
  63. 7.11.2 Synaptic Business Overview
  64. 7.11.3 Synaptic KI-67 Antibody Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Synaptic KI-67 Antibody Product Portfolio
  66. 7.11.5 Synaptic Recent Developments
  67. 7.12 United States Biological
  68. 7.12.1 United States Biological Company Information
  69. 7.12.2 United States Biological Business Overview
  70. 7.12.3 United States Biological KI-67 Antibody Revenue and Gross Margin (2021-2026)
  71. 7.12.4 United States Biological KI-67 Antibody Product Portfolio
  72. 7.12.5 United States Biological Recent Developments
  73. 7.13 Merck
  74. 7.13.1 Merck Company Information
  75. 7.13.2 Merck Business Overview
  76. 7.13.3 Merck KI-67 Antibody Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Merck KI-67 Antibody Product Portfolio
  78. 7.13.5 Merck Recent Developments
  79. 7.14 Thermo Fisher Scientific
  80. 7.14.1 Thermo Fisher Scientific Company Information
  81. 7.14.2 Thermo Fisher Scientific Business Overview
  82. 7.14.3 Thermo Fisher Scientific KI-67 Antibody Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Thermo Fisher Scientific KI-67 Antibody Product Portfolio
  84. 7.14.5 Thermo Fisher Scientific Recent Developments
8 North America
  1. 8.1 North America KI-67 Antibody Revenue (2021-2032)
  2. 8.2 North America KI-67 Antibody Revenue by Type (2021-2032)
  3. 8.2.1 North America KI-67 Antibody Revenue by Type (2021-2026)
  4. 8.2.2 North America KI-67 Antibody Revenue by Type (2027-2032)
  5. 8.3 North America KI-67 Antibody Revenue Share by Type (2021-2032)
  6. 8.4 North America KI-67 Antibody Revenue by Application (2021-2032)
  7. 8.4.1 North America KI-67 Antibody Revenue by Application (2021-2026)
  8. 8.4.2 North America KI-67 Antibody Revenue by Application (2027-2032)
  9. 8.5 North America KI-67 Antibody Revenue Share by Application (2021-2032)
  10. 8.6 North America KI-67 Antibody Revenue by Country
  11. 8.6.1 North America KI-67 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America KI-67 Antibody Revenue by Country (2021-2026)
  13. 8.6.3 North America KI-67 Antibody Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe KI-67 Antibody Revenue (2021-2032)
  2. 9.2 Europe KI-67 Antibody Revenue by Type (2021-2032)
  3. 9.2.1 Europe KI-67 Antibody Revenue by Type (2021-2026)
  4. 9.2.2 Europe KI-67 Antibody Revenue by Type (2027-2032)
  5. 9.3 Europe KI-67 Antibody Revenue Share by Type (2021-2032)
  6. 9.4 Europe KI-67 Antibody Revenue by Application (2021-2032)
  7. 9.4.1 Europe KI-67 Antibody Revenue by Application (2021-2026)
  8. 9.4.2 Europe KI-67 Antibody Revenue by Application (2027-2032)
  9. 9.5 Europe KI-67 Antibody Revenue Share by Application (2021-2032)
  10. 9.6 Europe KI-67 Antibody Revenue by Country
  11. 9.6.1 Europe KI-67 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe KI-67 Antibody Revenue by Country (2021-2026)
  13. 9.6.3 Europe KI-67 Antibody Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China KI-67 Antibody Revenue (2021-2032)
  2. 10.2 China KI-67 Antibody Revenue by Type (2021-2032)
  3. 10.2.1 China KI-67 Antibody Revenue by Type (2021-2026)
  4. 10.2.2 China KI-67 Antibody Revenue by Type (2027-2032)
  5. 10.3 China KI-67 Antibody Revenue Share by Type (2021-2032)
  6. 10.4 China KI-67 Antibody Revenue by Application (2021-2032)
  7. 10.4.1 China KI-67 Antibody Revenue by Application (2021-2026)
  8. 10.4.2 China KI-67 Antibody Revenue by Application (2027-2032)
  9. 10.5 China KI-67 Antibody Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia KI-67 Antibody Revenue (2021-2032)
  2. 11.2 Asia KI-67 Antibody Revenue by Type (2021-2032)
  3. 11.2.1 Asia KI-67 Antibody Revenue by Type (2021-2026)
  4. 11.2.2 Asia KI-67 Antibody Revenue by Type (2027-2032)
  5. 11.3 Asia KI-67 Antibody Revenue Share by Type (2021-2032)
  6. 11.4 Asia KI-67 Antibody Revenue by Application (2021-2032)
  7. 11.4.1 Asia KI-67 Antibody Revenue by Application (2021-2026)
  8. 11.4.2 Asia KI-67 Antibody Revenue by Application (2027-2032)
  9. 11.5 Asia KI-67 Antibody Revenue Share by Application (2021-2032)
  10. 11.6 Asia KI-67 Antibody Revenue by Country
  11. 11.6.1 Asia KI-67 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia KI-67 Antibody Revenue by Country (2021-2026)
  13. 11.6.3 Asia KI-67 Antibody Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA KI-67 Antibody Revenue (2021-2032)
  2. 12.2 SAMEA KI-67 Antibody Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA KI-67 Antibody Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA KI-67 Antibody Revenue by Type (2027-2032)
  5. 12.3 SAMEA KI-67 Antibody Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA KI-67 Antibody Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA KI-67 Antibody Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA KI-67 Antibody Revenue by Application (2027-2032)
  9. 12.5 SAMEA KI-67 Antibody Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA KI-67 Antibody Revenue by Country
  11. 12.6.1 SAMEA KI-67 Antibody Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA KI-67 Antibody Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA KI-67 Antibody Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst